67. Polycystic kidney disease Clinical trials / Disease details
Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05510115 (ClinicalTrials.gov) | October 17, 2022 | 11/8/2022 | Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease | Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney, Autosomal Dominant | Drug: Empagliflozin;Drug: Placebo | University of Colorado, Denver | University of Maryland | Not yet recruiting | 18 Years | 50 Years | All | 50 | Phase 2 | United States |